PATIENT-PHYSICIAN PERCEPTUAL GAPS IN MEDICATION-ADHERENCE AND TREATMENT-MANAGEMENT PRIORITIES IN SEVERE ASTHMA AND CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Author(s)
Ioannis J. Yfantopoulos, II, DPhil1, Jannis Constantinidis, Ph.D.2, Michael Makris, Ph.D.3, Constantinos, Glynos, Ph.D.4, Vasiliki Stamatopoulou, Ph.D.4, Maria Pastra, Master of Science4, Loukidis Stelios, Ph.D.5.
1Professor of Health Economics, University of Athens, Ekali, Greece, 2Aristotle University of Thessaloniki, Thessaloniki, Greece, 3Medical School, National and Kapodistrian University of Athens Medical School, Athens, Greece, 4GSK Pharmaceuticals Greece, Athens, Greece, 5National and Kapodistrian University of Athens Medical School, Athens, Greece.
1Professor of Health Economics, University of Athens, Ekali, Greece, 2Aristotle University of Thessaloniki, Thessaloniki, Greece, 3Medical School, National and Kapodistrian University of Athens Medical School, Athens, Greece, 4GSK Pharmaceuticals Greece, Athens, Greece, 5National and Kapodistrian University of Athens Medical School, Athens, Greece.
OBJECTIVES: To assess patient-physician perceptual discordance regarding medication-adherence barriers and treatment-management priorities in severe asthma (SA) and chronic rhinosinusitis with nasal polyps (CRSwNP).
METHODS: A multicenter, cross-sectional survey conducted in Greece included two distinct cohorts: 556 patients (442 with SA and 114 with CRSwNP) who reported their own treatment experiences, and 151 physicians (88 treating SA and 63 treating CRSwNP) estimating the average experience of patients under their care. Patient-physician differences in ASK-12 outcomes, determinants of long-term adherence, treatment-management priorities, and communication preferences were evaluated.
RESULTS: Overall adherence was assessed by physicians at 69.6 ± 22.1% in SA and 62.3 ± 22.9% in CRSwNP. Physicians perceived higher levels of adherence barriers for their patients than the patients themselves in both conditions. Median ASK-12 total adherence barrier scores reported by physicians were significantly higher than those reported by patients (32.5 vs 26.0 in SA; 33.0 vs 26.0 in CRSwNP; both p<0.001). In SA, physicians compared with patients, more frequently prioritized treatment effectiveness (96.6% vs 84.6%; p=0.003), safety (94.3% vs 85.5%; p=0.025), and physician-patient shared decision-making regarding biologic therapy (93.2% vs 83.0%; p=0.016). In CRSwNP, both groups highly prioritized effectiveness and safety without significant differences; however, greater divergence was observed regarding physician-patient shared decision-making on biologic therapy (92.1% vs 71.7%; p=0.002).
CONCLUSIONS: This study highlights important patient-physician perceptual gaps regarding medication-adherence barriers in both SA and CRSwNP, with physicians consistently perceiving greater barriers than patients per disease respectively. Treatment-management priorities were largely aligned, particularly concerning treatment effectiveness, safety, and agreement on biologic-treatment selection. The findings underscore the importance of incorporating patient-reported adherence assessments into routine clinical care and strengthening shared decision-making processes, to attain sustainable treatments for optimum patient outcomes.
METHODS: A multicenter, cross-sectional survey conducted in Greece included two distinct cohorts: 556 patients (442 with SA and 114 with CRSwNP) who reported their own treatment experiences, and 151 physicians (88 treating SA and 63 treating CRSwNP) estimating the average experience of patients under their care. Patient-physician differences in ASK-12 outcomes, determinants of long-term adherence, treatment-management priorities, and communication preferences were evaluated.
RESULTS: Overall adherence was assessed by physicians at 69.6 ± 22.1% in SA and 62.3 ± 22.9% in CRSwNP. Physicians perceived higher levels of adherence barriers for their patients than the patients themselves in both conditions. Median ASK-12 total adherence barrier scores reported by physicians were significantly higher than those reported by patients (32.5 vs 26.0 in SA; 33.0 vs 26.0 in CRSwNP; both p<0.001). In SA, physicians compared with patients, more frequently prioritized treatment effectiveness (96.6% vs 84.6%; p=0.003), safety (94.3% vs 85.5%; p=0.025), and physician-patient shared decision-making regarding biologic therapy (93.2% vs 83.0%; p=0.016). In CRSwNP, both groups highly prioritized effectiveness and safety without significant differences; however, greater divergence was observed regarding physician-patient shared decision-making on biologic therapy (92.1% vs 71.7%; p=0.002).
CONCLUSIONS: This study highlights important patient-physician perceptual gaps regarding medication-adherence barriers in both SA and CRSwNP, with physicians consistently perceiving greater barriers than patients per disease respectively. Treatment-management priorities were largely aligned, particularly concerning treatment effectiveness, safety, and agreement on biologic-treatment selection. The findings underscore the importance of incorporating patient-reported adherence assessments into routine clinical care and strengthening shared decision-making processes, to attain sustainable treatments for optimum patient outcomes.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR35
Topic
Clinical Outcomes, Methodological & Statistical Research, Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance, Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)